High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

Stanford University300 enrolled

Overview

To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.

To assess the toxicity and efficacy of sequentially administered high dose cyclophosphamide and VP-16 followed by total body irradiation or BCNU and high dose mephalan and autologous stem cell rescue in the treatment of multiple myeloma.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

300

Conditions

Multiple Myeloma

Interventions

high dose chemotherapy then autologous hematopoietic cell transplantPROCEDURE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria:- received cytoreduction prior to transplant * adequate organ function Exclusion Criteria:- previous transplant * smoldering MM or benign monoclonal gammopathy

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Outcomes

Primary Outcomes

Toxicity and efficacy of sequentially administered high dose chemotherapy and autologous hematopoietic cell transplantation

Time frame: Patients will have a daily CBC with platelet count, and chemistries until engraftment, then as indicated clinically. Chest x-rays will be done weekly until engraftment, then as indicated clinically. Patients will be restaged for abnormal proteins (SPIE)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.